We are international
Donate
TEXT SIZE   


Smoldering Myeloma (high risk)
07.18.11
    • Smoldering myeloma (high risk) - This is the group of patients of greatest concern. Current definitions indicate that approximately 50% of patients will develop myeloma within 18-24 months. Better definitions are being proposed using bone marrow immunophenotyping, bone imaging (MRI/PET/CT), Hevylite®, GEP and microRNA, which may give better prediction at the > 90% level, which will provide a better basis for clinical decision making. In this situation, earlier treatment intervention could be recommended with greater confidence. This is an area of active clinical research.
    Table 3 - Smoldering or Indolent Myeloma Diagnostic Criteria: All Three Required

    1. Monoclonal protein present in the serum and/or urine
    2. Monoclonal plasma cells present in the bone marrow and/or a tissue biopsy
    3.

    Not meeting criteria for MGUS, multiple myeloma, or solitary plasmacytoma of bone or soft tissue


    * These criteria identify Stage IA myeloma by Durie/Salmon stage.

 related articles
Insights into Smoldering (Asymptomatic) Multiple Myeloma
What is Smoldering Myeloma?
ASH 2011: Dr. Mateos - Smoldering Multiple Myeloma (SMM) At High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) As Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment
High-Risk Smoldering Myeloma Addressed by Group 1 during Second Annual International Myeloma Working Group Summit


You might also be interested in:

Insights into Smoldering (Asymptomatic) Multiple Myeloma
An ASCO Connection Current Controversies in Oncology article featuring Dr. Kyle of the Mayo Clinic.

What is Smoldering Myeloma?
Dr. Ola Landgren
National Cancer Institute
Bethesda, Maryland

ASH 2011: Dr. Mateos - Smoldering Multiple Myeloma (SMM) At High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) As Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment
María-Victoria Mateos, MD, PhD
Hospital Clinico Universitario
Salamanca, Spain

High-Risk Smoldering Myeloma Addressed by Group 1 during Second Annual International Myeloma Working Group Summit
How to maximize benefits of early treatment for patients with high-risk smoldering myeloma, yet avoid unnecessary treatment and toxicities.